Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Inks Service Agreement with GSK

NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed a commercial service agreement with GlaxoSmithKline in the area of cancer metabolomics.

Under the agreement, Cambridge, UK-based Horizon will use its X-MAN cell lines to provide GSK with services including the characterization of biomarkers, disease signatures, and therapeutic targets.

Financial terms of the agreement were not disclosed.

Horizon said that its X-MAN isogenic cell lines provide genetically defined and patient-relevant in vitro models of human cancer to help companies discover and develop targeted or personalized cancer therapeutics.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.